Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Hematopoietic and Lymphoid Cell Neoplasm

Hematopoietic and Lymphoid Cell Neoplasm — NIH Grants & Funding

Active and recent NIH-funded research on Hematopoietic and Lymphoid Cell Neoplasm. Data from NIH RePORTER, last 36 months.

MONDO:0044881

NIH-funded research on Hematopoietic and Lymphoid Cell Neoplasm

143

active grants

institutions

207

researchers

new in last 12 mo.

$132.0M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(85)

Basic ScienceR01Active

Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia

Loh, Mignon et al.·SEATTLE CHILDREN'S HOSPITAL·SEATTLE, WA

$3,480,276 (FY2025)

Hematopoietic and Lymphoid Cell Neoplasm — NIH Grants & Funding

Basic Science(85)

Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia

TYK2 Fusions in Lymphoma

Immunotherapy of low grade lymphoid malignancies

Molecular and Cellular Regulation of Pre-Leukemic Stem Cells and their Therapeutic Targeting

Defining the Roles of Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple Myeloma Drug Resistance

DNMT3A in Development of Hematologic Malignancies

Ikaros regulation: study on hemo-lymphopoiesis

Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia

High resolution lineage tracing of developmental hematopoiesis

TET2-mediated epitranscriptomic regulation in leukemia microenvironment

Translational(39)

Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19

Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge

Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant

Combining Targeted RIT and Synergistic Novel Agent-Renewal

Investigation of underlying mechanisms and novel therapies for human acquired and congenital disorders of hematopoiesis

Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia

Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia

Selective targeting of TAF1 function in acute myeloid leukemia

Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant

New tools for quantitative non-invasive recording of biochemical signals

Clinical(20)

Clinical and translational studies of RUNX1 and FPDMM

Understanding and Targeting Aberrant RNA Splicing in Leukemia

Preventing GVHD by inhibition of alloantigen presentation in the gut

Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2

Mechanistic Insight to Predict and Prevent Nilotinib-Induced Artery Disease

Donor health-related quality-of-life and physician decision-making in the context of haploidentical hematopoietic stem cell transplantation (HaploQOL)

Sleep Disordered Breathing as a Targetable Risk Factor in Multiple Myeloma

Time-restricted eating to address cancer-related fatigue among survivors of hematological malignancies

Pathways of Immune Evasion in Acute Myeloid Leukemia

Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention

Epi / Nat. History(8)

Molecular prediction of myeloma in African Americans

Genetic Origins of Adverse Outcomes in African Americans with Lymphoma

Novel mechanisms of B cell tumorigenesis and relapse

Dissecting the role of germline genetic variation and viral exposures as determinants of hematological disease predisposition

Mechanisms underlying increased risk of hematological malignancy in sickle cell disease.

Investigating immunophenotype and metabolism of TCR KO donor and third-party CD19-targeted chimeric antigen receptor T cells

The role of inflammation in driving leukemogenesis in germline predisposition syndromes

New Multi-Drug Resistance Mechanism in Multiple Myeloma

Gene/Cell Therapy(14)

Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy

Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies

Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells

Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Differences in Tumor Biology of Multiple Myeloma

BMT Core- The Ohio State University blood and marrow transplant research consortium

Cellular engineering to improve the efficacy and specificity of targeted immunotherapy

Establishing CUX1 as a determinant of Hematopoietic Stem cell heterogeneity

Structure-guided protein evolution to develop improved natural ligand-based chimeric antigen receptor T cell therapy against CD70 in acute myeloid leukemia

Engineering best in class Acute Myeloid Leukemia (AML) CAR-T therapies by enhancing persistence and defining the immune landscape of AML

Biomarker / Dx(9)

Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing

Molecular Pathogenesis of Acute Myeloid Leukemia

The IL-18-IFNγ axis predicts response to immunotherapy

A low-cost, multiplexed digital high resolution melt platform for DNA methylation-based detection and identification of cancers in liquid biopsies

Flow cytometric detection of malignant cells in body fluids

Understanding the communication between cancer cells and cancer-associated fibroblasts in chronic lymphocytic leukemia: roles clarification and therapeutic targets exploration

Dissecting the Roles of PPM1D and TP53 in Hematopoietic Stem Cells and Clonal Hematopoiesis

Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkit

Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing

Other(4)

Proteostasis regulators in blood cell development and function

Identifying Multi-Level Predictors and Outcomes of Oral Anticancer Medication Adherence Initiation and Persistence among Patients with Hematologic Malignancies

CCSG - Administrative Supplement - ECIA

Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms